Literature DB >> 18703664

Immune properties of human umbilical cord Wharton's jelly-derived cells.

Mark L Weiss1, Cameron Anderson, Satish Medicetty, Kiran B Seshareddy, Rita J Weiss, Irene VanderWerff, Deryl Troyer, Kevin R McIntosh.   

Abstract

Cells isolated from Wharton's jelly, referred to as umbilical cord matrix stromal (UCMS) cells, adhere to a tissue-culture plastic substrate, express mesenchymal stromal cell (MSC) surface markers, self-renew, and are multipotent (differentiate into bone, fat, cartilage, etc.) in vitro. These properties support the notion that UCMS cells are a member of the MSC family. Here, the immune properties of UCMS cells are characterized in vitro. The overall hypothesis is that UCMS cells possess immune properties that would be permissive to allogeneic transplantation. For example, UCMS cells will suppress of the proliferation of "stimulated" lymphocytes (immune suppression) and have reduced immunogenicity (e.g., would be poor stimulators of allogeneic lymphocyte proliferation). Hypothesis testing was as follows: first, the effect on proliferation of coculture of mitotically inactivated human UCMS cells with concanavalin-A-stimulated rat splenocytes was assessed in three different assays. Second, the effect of human UCMS cells on one-way and two-way mixed lymphocyte reaction (MLR) assays was determined. Third, the expression of human leukocyte antigen (HLA)-G was examined in human UCMS cells using reverse transcription-polymerase chain reaction, since HLA-G expression conveys immune regulatory properties at the maternal-fetal interface. Fourth, the expression of CD40, CD80, and CD86 was determined by flow cytometry. Fifth, the cytokine expression of UCMS cells was evaluated by focused gene array. The results indicate that human UCMS cells inhibit splenocyte proliferation response to concanavalin A stimulation, that they do not stimulate T-cell proliferation in a one-way MLR, and that they inhibit the proliferation of stimulated T cells in a two-way MLR. Human UCMS cells do not inhibit nonstimulated splenocyte proliferation, suggesting specificity of the response. UCMS cells express mRNA for pan-HLA-G. UCMS cells do not express the costimulatory surface antigens CD40, CD80, and CD86. UCMS cells express vascular endothelial growth factor and interleukin-6, molecules previously implicated in the immune modulation observed in MSCs. In addition, the array data indicate that UCMS cells make a cytokine and other factors that may support hematopoiesis. Together, these results support previous observations made following xenotransplantation; for example, there was no evidence of frank immune rejection of undifferentiated UCMS cells. The results suggest that human UCMS will be tolerated in allogeneic transplantation. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703664     DOI: 10.1634/stemcells.2007-1028

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  190 in total

1.  Evaluation of the cell viability of human Wharton's jelly stem cells for use in cell therapy.

Authors:  Ingrid Garzón; Barbara Pérez-Köhler; Juan Garrido-Gómez; Victor Carriel; Renato Nieto-Aguilar; Miguel Angel Martín-Piedra; Natalio García-Honduvilla; Julia Buján; Antonio Campos; Miguel Alaminos
Journal:  Tissue Eng Part C Methods       Date:  2012-01-26       Impact factor: 3.056

2.  Evaluation of suitable reference gene for real-time PCR in human umbilical cord mesenchymal stem cells with long-term in vitro expansion.

Authors:  Youwei Wang; Zhibo Han; Shulin Yan; Aibin Mao; Bin Wang; He Ren; Ying Chi; Zhongchao Han
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-05-04       Impact factor: 2.416

3.  Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice.

Authors:  Chiyo Doi; Dharmendra Kumar Maurya; Marla M Pyle; Deryl Troyer; Masaaki Tamura
Journal:  Cytotherapy       Date:  2010-05       Impact factor: 5.414

Review 4.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 5.  Emerging topics and new perspectives on HLA-G.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Marina Stignani; Fabio Morandi; Gwenaëlle Sana; Rafael Gonzalez; Vito Pistoia; Olavio Roberto Baricordi; Etienne Sokal; Josè Peña
Journal:  Cell Mol Life Sci       Date:  2010-11-16       Impact factor: 9.261

Review 6.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

7.  Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes.

Authors:  Changhui Zhou; Bo Yang; Yi Tian; Hongliang Jiao; Wendi Zheng; Jian Wang; Fangxia Guan
Journal:  Cell Immunol       Date:  2011-09-29       Impact factor: 4.868

8.  Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.

Authors:  Limin Wang; Mark L Weiss; Michael S Detamore
Journal:  Recent Pat Regen Med       Date:  2013

Review 9.  Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials.

Authors:  Ana Maria Blanco Martinez; Camila de Oliveira Goulart; Bruna Dos Santos Ramalho; Júlia Teixeira Oliveira; Fernanda Martins Almeida
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 10.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.